Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tailored Sonidegib Schedule After Complete Response in BCC (SONIBEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04806646
Recruitment Status : Recruiting
First Posted : March 19, 2021
Last Update Posted : March 19, 2021
Sponsor:
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest

Brief Summary:
Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors are administered a tailored schedule of the study drug. The tailored schedule consists of a change in the time of drug assumption. It implements some weeks of assumption and some weeks of suspension of sonidegib rather than a continuous administration.

Condition or disease Intervention/treatment Phase
Locally Advanced Basal Cell Carcinoma Drug: Sonidegib Phase 2

Detailed Description:

One cycle of therapy is defined as 28 days of sonidegib. The patient will start with first schedule.

  • Treatment schedule 1 (TS1): assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.
  • Treatment schedule 2 (TS2): assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.

If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-label Study Improving Compliance and Time of Treatment After Obtaining Complete Response Through a Tailored Schedule of Sonidegib in Locally Advanced Basal Cell Carcinomas (BCC) - the SONIBEC Trial
Actual Study Start Date : January 12, 2021
Estimated Primary Completion Date : January 12, 2024
Estimated Study Completion Date : January 12, 2026

Resource links provided by the National Library of Medicine

Drug Information available for: Sonidegib

Arm Intervention/treatment
Experimental: Single Arm Treatment

One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.

  • TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.
  • TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.

If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study.

Drug: Sonidegib
TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
Other Name: Odomzo




Primary Outcome Measures :
  1. Maintaining tailored treatment [ Time Frame: 12 months ]
    Proportion of patients maintaining the tailored treatment with sonidegib 12 months after enrolment into the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written, signed informed consent, including consent to photographs of lesions.
  2. Age ≥ 18 years.
  3. Histologic confirmation of locally advanced BCC lesion.
  4. Patients with BCCs already in treatment with Hedgehog inhibitor sonidegib for:

    • BCC that has recurred in the same location after three or more surgical procedures and/or curative resection is deemed unlikely
    • multifocal BCC or extensive tumours with bleeding or infected areas
    • anticipated substantial morbidity and/or deformity from surgery (e.g. removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation)
    • multiple BCCs not amenable to surgical treatment because of oncologic or clinical reasons
  5. Patient having shown a complete response (CR) to Hedgehog inhibitor sonidegib within the 3 months prior to the screening. In BCC every effort should be made to obtain histologic confirmation of CR mainly in case of doubt, performing several biopsies in the sites where disease was present. CR must have been confirmed by 2 consecutive radiologic exams and by visual and dermoscopic examinations.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  7. Adequate hematopoietic capacity, defined as the following:

    • Haemoglobin > 8.5 g/dl
    • Absolute neutrophil count (ANC) ≥ 1000/mmc
    • Platelet count ≥ 75,000/mmc
  8. Adequate hepatic and renal function, defined as the following:

    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented Gilbert syndrome
    • Calculated serum creatinine clearance (CrCl) ≥ 30 mL/min
  9. For women of childbearing potential, a negative pregnancy test within 7 days prior to commencement of dosing is required
  10. Women of child-bearing potential must use two methods of acceptable contraception including one highly effective method and a barrier method, as directed by their physician, during treatment and for at least 20 months after completion of study treatment. Highly effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (e.g., implants, injectables, combined oral contraception, or intra-uterine devices). Check Appendix B for details.
  11. Participant must agree to not breastfeed during the study and for 20 months after the last dose of study treatment.
  12. For male patients with female partners of childbearing potential, agreement to use a condom, even after a vasectomy, during sexual intercourse with female partners while being treated with sonidegib, and for 6 months after the last dose was received.
  13. Agreement not to donate blood or blood products during the study and for at least 20 months after the last dose was received.
  14. For male patients, agreement not to donate sperm during treatment and for 6 months after the last dose was received.

Exclusion Criteria:

  1. Metastatic BCC.
  2. Inability or unwillingness to swallow capsules.
  3. Inability or unwillingness to comply with study procedures.
  4. Pregnancy or lactation.
  5. Concurrent non-protocol-specified anti-tumour therapy (e.g., chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy, including participation in an experimental drug study).
  6. Uncontrolled medical illness, including advanced malignancies, at the discretion of the Investigator.
  7. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04806646


Contacts
Layout table for location contacts
Contact: Mariarita Arenella +39 089 301545 | sonibec@cr-technology.com

Locations
Layout table for location information
Italy
Asst Degli Spedali Civili Di Brescia Recruiting
Brescia, Italy
Contact: Paolo Bossi    +390303996879    paolo.bossi@unibs.it   
Sponsors and Collaborators
Gruppo Oncologico del Nord-Ovest
Investigators
Layout table for investigator information
Principal Investigator: Paolo Bossi, MD Gono - ASST Spedali Civili Brescia
Layout table for additonal information
Responsible Party: Gruppo Oncologico del Nord-Ovest
ClinicalTrials.gov Identifier: NCT04806646    
Other Study ID Numbers: SONIBEC
First Posted: March 19, 2021    Key Record Dates
Last Update Posted: March 19, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell